MK-3475-671/KEYNOTE-671

Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer

aktiv

3

Asklepios Klinikum Harburg

§116b-Ambulanz Thoraxonkologie
Eißendorfer Pferdeweg 52
21075 Hamburg

Tel: 040 / 1818 86-3470
Fax: 040 / 1818 86-2772

Dr. med. Claas Wesseler

Vorherige Studie
Nächste Studie
to top icon